Bivatuzumab (Anti-CD44 Recombinant Antibody, BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].
Molecular Weight:
(143.22 kDa)
Purity:
99.82
CAS Number:
[214559-60-1]
Target:
Others
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted